Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat

Transplant Immunology
L ZezinaB Fellström

Abstract

To date established treatment of transplant arteriosclerosis is basically missing and there is a need for new therapeutic approaches. Angiotensin II (Ang II) and Ang II receptor type 1 (AT) are present in the vascular wall. Blocking of the AT1 receptor by pharmacological agents may inhibit damaging effects of Ang II on endothelial and smooth muscle cells. The purpose of the study was to evaluate the effect of the AT1 receptor blocker Candesartan cilexetil on the development of graft arteriosclerosis in a rat aortic transplant model. Two strain combinations were used for aortic transplantation: DA to PVG; and PVG to PVG. The animals received Candesartan cilexetil treatment (9.5 + 1.4 mg/kg/day) for 8 weeks. Candesartan cilexetil treatment reduced neointimal formation both in allografts (Qint 30.2 +/- 8.8% vs. 22.1 +/- 8.7%, P < 0.05) and in isografts (Qint 15.5 +/- 4.4% vs. 6.7 +/- 3.3%, P = 0.0001). Blocking of the AT1 receptor signalling by Candesartan cilexetil was also associated with a reduced expression of TGF-beta1. Macrophage infiltration was not affected by the treatment. Candesartan cilexetil treatment leads to reduced neointimal formation in aortic transplant. The positive effect of the drug might be partly explained ...Continue Reading

References

May 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·A MennanderP Häyry
Mar 1, 1994·The Journal of Clinical Investigation·Y G WolfE Ruoslahti
Dec 1, 1996·Arteriosclerosis, Thrombosis, and Vascular Biology·J WaltenbergerK Funa
Jul 9, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·R KranzhöferW Kübler
Feb 2, 2000·Transplant International : Official Journal of the European Society for Organ Transplantation·D M LittleD A Hullett

❮ Previous
Next ❯

Citations

Jan 15, 2009·Canadian Journal of Physiology and Pharmacology·Yong-Qi LiQiu-Ju Huang
Jan 2, 2010·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Hisanori KosugeMitsuaki Isobe
Jan 25, 2005·Transplantation·Bengt FellströmUNKNOWN Assessment of Lescol in Renal Transplantation Study Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.